Literature DB >> 28885922

Management of Acute Diarrheal Illness During Deployment: A Deployment Health Guideline and Expert Panel Report.

Mark S Riddle1, Gregory J Martin2, Clinton K Murray3, Timothy H Burgess4, Patrick Connor5, James D Mancuso6, Elizabeth R Schnaubelt7, Timothy P Ballard8, Jamie Fraser4, David R Tribble4.   

Abstract

BACKGROUND: Acute diarrheal illness during deployment causes significant morbidity and loss of duty days. Effective and timely treatment is needed to reduce individual, unit, and health system performance impacts.
METHODS: This critical appraisal of the literature, as part of the development of expert consensus guidelines, asked several key questions related to self-care and healthcare-seeking behavior, antibiotics for self-treatment of travelers' diarrhea, what antibiotics/regimens should be considered for treatment of acute watery diarrhea and febrile diarrhea and/or dysentery, and when and what laboratory diagnostics should be used to support management of deployment-related travelers' diarrhea. Studies of acute diarrhea management in military and other travelers were assessed for relevance and quality. On the basis of this critical appraisal, guideline recommendations were developed and graded by the Expert Panel using good standards in clinical guideline development methodology.
RESULTS: New definitions for defining the severity of diarrhea during deployment were established. A total of 13 graded recommendations on the topics of prophylaxis, therapy and diagnosis, and follow-up were developed. In addition, four non-graded consensus-based statements were adopted.
CONCLUSIONS: Successful management of acute diarrheal illness during deployment requires action at the provider, population, and commander levels. Strong evidence supports that single-dose antimicrobial therapy is effective in most cases of moderate to severe acute diarrheal illness during deployment. Further studies are needed to address gaps in available knowledge regarding optimal therapies for treatment, prevention, and laboratory testing of acute diarrheal illness. Reprint &
Copyright © 2017 Association of Military Surgeons of the U.S.

Entities:  

Mesh:

Year:  2017        PMID: 28885922      PMCID: PMC5657341          DOI: 10.7205/MILMED-D-17-00077

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  153 in total

1.  Single dose of azithromycin or three-day course of ciprofloxacin as therapy for epidemic dysentery in Kenya. Acute Dysentery Study Group.

Authors:  G D Shanks; B L Smoak; G M Aleman; J Oundo; P G Waiyaki; M W Dunne; L Petersen
Journal:  Clin Infect Dis       Date:  1999-10       Impact factor: 9.079

2.  Oral rehydration therapy plus loperamide versus loperamide alone in the treatment of traveler's diarrhea.

Authors:  J P Caeiro; H L DuPont; H Albrecht; C D Ericsson
Journal:  Clin Infect Dis       Date:  1999-06       Impact factor: 9.079

3.  Travellers' diarrhoea: a military problem?

Authors:  P Connor; M J Farthing
Journal:  J R Army Med Corps       Date:  1999-06       Impact factor: 1.285

4.  Practice guidelines for the management of infectious diarrhea.

Authors:  R L Guerrant; T Van Gilder; T S Steiner; N M Thielman; L Slutsker; R V Tauxe; T Hennessy; P M Griffin; H DuPont; R B Sack; P Tarr; M Neill; I Nachamkin; L B Reller; M T Osterholm; M L Bennish; L K Pickering
Journal:  Clin Infect Dis       Date:  2001-01-30       Impact factor: 9.079

5.  Optimal dosing of ofloxacin with loperamide in the treatment of non-dysenteric travelers' diarrhea.

Authors:  C D Ericsson; H L DuPont; J J Mathewson
Journal:  J Travel Med       Date:  2001 Jul-Aug       Impact factor: 8.490

6.  A multicenter randomized controlled trial of a liquid loperamide product versus placebo in the treatment of acute diarrhea in children.

Authors:  M A Kaplan; M J Prior; K I McKonly; H L DuPont; A R Temple; E B Nelson
Journal:  Clin Pediatr (Phila)       Date:  1999-10       Impact factor: 1.168

Review 7.  Antibiotic treatment for travellers' diarrhoea.

Authors:  G De Bruyn; S Hahn; A Borwick
Journal:  Cochrane Database Syst Rev       Date:  2000

8.  Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial.

Authors:  H L DuPont; Z D Jiang; C D Ericsson; J A Adachi; J J Mathewson; M W DuPont; E Palazzini; L M Riopel; D Ashley; F Martinez-Sandoval
Journal:  Clin Infect Dis       Date:  2001-10-23       Impact factor: 9.079

9.  The safety of azithromycin in the treatment of adults with community-acquired respiratory tract infections.

Authors:  Glenda Treadway; Dennis Pontani; Arlene Reisman
Journal:  Int J Antimicrob Agents       Date:  2002-03       Impact factor: 5.283

10.  Imported malaria treated in Melbourne, Australia: epidemiology and clinical features in 246 patients.

Authors:  P Robinson; A W Jenney; M Tachado; A Yung; J Manitta; K Taylor; B A Biggs
Journal:  J Travel Med       Date:  2001 Mar-Apr       Impact factor: 8.490

View more
  10 in total

1.  Deployment Infectious Disease Threats: IDCRP Initiatives and Vision Forward.

Authors:  Tahaniyat Lalani; Jamie Fraser; Mark S Riddle; Ramiro L Gutierrez; Patrick W Hickey; David R Tribble
Journal:  Mil Med       Date:  2019-11-01       Impact factor: 1.437

2.  A disease severity scale for the evaluation of vaccine and other preventive or therapeutic interventions for travellers' diarrhoea.

Authors:  Nicole Maier; Mark S Riddle; Ramiro Gutiérrez; Jamie A Fraser; Patrick Connor; David R Tribble; Chad K Porter
Journal:  J Travel Med       Date:  2022-01-17       Impact factor: 39.194

3.  Clinical endpoints in the controlled human challenge model for Shigella: A call for standardization and the development of a disease severity score.

Authors:  Chad K Porter; Amanda Lynen; Mark S Riddle; Kawsar Talaat; David Sack; Ramiro L Gutiérrez; Robin McKenzie; Barbara DeNearing; Brittany Feijoo; Robert W Kaminski; David N Taylor; Beth D Kirkpatrick; A Louis Bourgeois
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

4.  Infectious diseases during the European Union training mission Mali (EUTM MLI) - a four-year experience.

Authors:  Hagen Frickmann; Ralf Matthias Hagen; Florian Geiselbrechtinger; Nagpal Hoysal
Journal:  Mil Med Res       Date:  2018-05-31

5.  Antibiotic Resistance of Campylobacter Species in a Pediatric Cohort Study.

Authors:  Francesca Schiaffino; Josh M Colston; Maribel Paredes-Olortegui; Ruthly François; Nora Pisanic; Rosa Burga; Pablo Peñataro-Yori; Margaret N Kosek
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

6.  Fecal Microbiota Functional Gene Effects Related to Single-Dose Antibiotic Treatment of Travelers' Diarrhea.

Authors:  Ryan C Johnson; Joy D Van Nostrand; Michele Tisdale; Brett Swierczewski; Mark P Simons; Patrick Connor; Jamie Fraser; Angela R Melton-Celsa; David R Tribble; Mark S Riddle
Journal:  Open Forum Infect Dis       Date:  2021-05-28       Impact factor: 3.835

Review 7.  Gut Microbiota, Its Role in Induction of Alzheimer's Disease Pathology, and Possible Therapeutic Interventions: Special Focus on Anthocyanins.

Authors:  Muhammad Sohail Khan; Muhammad Ikram; Jun Sung Park; Tae Ju Park; Myeong Ok Kim
Journal:  Cells       Date:  2020-04-01       Impact factor: 6.600

Review 8.  Effects of Psychological, Environmental and Physical Stressors on the Gut Microbiota.

Authors:  J Philip Karl; Adrienne M Hatch; Steven M Arcidiacono; Sarah C Pearce; Ida G Pantoja-Feliciano; Laurel A Doherty; Jason W Soares
Journal:  Front Microbiol       Date:  2018-09-11       Impact factor: 5.640

Review 9.  Intestinal in vitro and ex vivo Models to Study Host-Microbiome Interactions and Acute Stressors.

Authors:  Sarah C Pearce; Heidi G Coia; J P Karl; Ida G Pantoja-Feliciano; Nicholas C Zachos; Kenneth Racicot
Journal:  Front Physiol       Date:  2018-11-12       Impact factor: 4.566

10.  Doxycycline Malaria Prophylaxis Impact on Risk of Travelers' Diarrhea among International Travelers.

Authors:  Kathryn Lago; Kalyani Telu; David Tribble; Anuradha Ganesan; Anjali Kunz; Charla Geist; Jamie Fraser; Indrani Mitra; Tahaniyat Lalani; Heather C Yun
Journal:  Am J Trop Med Hyg       Date:  2020-11       Impact factor: 2.345

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.